How much funding has Valthos raised?

Valthos has raised $30 million in total funding. Their latest funding round was Seed. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

Where is Valthos headquartered?

Valthos is headquartered in New York, USA. The company has a team of 11-50 people.

What does Valthos do?

Valthos operates in the AI in Healthcare sector. AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons Provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures

When was Valthos founded?

Valthos was founded in 2024. It is based in New York, USA.

How much funding has Valthos raised?

Valthos has raised $30 million in total funding. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

Who is the CEO of Valthos?

Kathleen McMahon is the CEO of Valthos. The company was founded in 2024.

Where is Valthos located?

Valthos is headquartered in New York, USA.

What funding stage is Valthos at?

Valthos is currently at the Early Stage stage.

How many employees does Valthos have?

Valthos has approximately 11-50 employees.

Valthos

Category: AI in Healthcare

AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons Valthos was founded in 2024. The company is led by Kathleen McMahon. Based in New York, USA. Team size: 11-50. Total funding raised: $30 million. Latest round: Seed. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

AMW Analysis

Valthos is an AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons. It provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures. Founded in 2024 and based in New York, the company raised a $30 million Seed round from investors including OpenAI Startup Fund, Lux Capital, and Founders Fund.

The recent news flow centers on this single funding event, which is described as a critical shift in the AI safety narrative, moving beyond abstract risk discussions to funding practical, defensive applications. The investment signals that AI is being positioned as a defensive layer against catastrophic, synthetic biological threats. The news also notes that Valthos aims to deploy AI for rapid threat detection and real-time medical countermeasures, marking a pivot where major AI developers actively fund "countervailing technologies" to mitigate bioweapon risks. The company has not announced any additional products, partnerships, or subsequent rounds in the tracked news.

AMW analysis, generated from 3 tracked news signals.

Founded: 2024
Headquarters: New York, USA
Team size: 11-50
Total funding: $30 million

Value proposition

Provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures

Products and solutions

AI-powered threat detection platform with real-time sequencing and environmental data ingestion, Automated countermeasure design engine that proposes vaccine or therapeutic candidates

Unique value

Exclusive focus on AI-enabled detection of deliberately engineered biothreats, offering real-time countermeasure design - a capability not present in broader pandemic-surveillance platforms

Target customer

Government agencies (HHS, CDC, DHS), international health organizations (WHO), and large life-science corporations needing advanced bio-threat monitoring

Industries served

Biosecurity, Biodefense, Government, Public Health, Life Sciences

Technology advantage

Combines frontier large-language-model AI (access to OpenAI's models) with proprietary bioinformatics pipelines, enabling detection of engineered sequences that evade traditional signature-based methods

How they differentiate

Focuses specifically on using AI to detect and counter AI-engineered biological threats in real-time, moving beyond general pandemic surveillance to address deliberate misuse of AI in creating bioweapons

Main competitors

Ginkgo Bioworks, Metabiota, Palantir, BlueDot, HealthMap

Notable customers

U.S. Department of Defense (DoD), Los Alamos National Laboratory

Major milestones

October 2025 - Emerged from stealth with $30M seed from OpenAI Startup Fund, Lux Capital, Founders Fund, July 2026 - Named to Forbes Next Billion-Dollar Startups 2026 list (valuation $200M+), 2026 - Publicly cited clients include U.S. Department of Defense and Los Alamos Labs

Growth metrics

~15-16 employees (PitchBook 15; Tracxn 16 as of Jun 2026; LinkedIn 11-50), Forbes-cited valuation $200M+, still seed-stage; no public revenue or ARR disclosed

Market positioning

Positioned as a pioneer in AI-driven biodefense, leveraging high-profile investors and government partnerships to become the go-to platform for national security bio-threat monitoring

Geographic focus

Primary focus on the United States with potential for collaboration with allied nations

About Kathleen McMahon

Former Head of Life Sciences at Palantir Technologies (Aug 2017–Nov 2024); previously Equity Research Analyst at Goldman Sachs (2015–2017); education includes Georgetown University

Latest news about Valthos

More AI in Healthcare companies

Official website: https://valthos.com